Multi-Omics Technologies in OCLNM Assessment

The contemporary integration of multi-omics technologies in OCLNM assessment is focused on translating multidimensional molecular data into clinically actionable predictive tools and algorithmic inputs.

Genomics and Epigenetics: The Molecular Bedrock

At present, to predict the risk of OCLNM, targeted next-generation sequencing and epigenetic microarrays are used to construct quantitative risk-stratification models. For instance, genomic panels demonstrating 11q13 amplification (encompassing driver genes such as CCND1, CTTN, and FADD) have been used to identify patients requiring aggressive prophylactic neck dissection [33, 34]. More importantly, DNA methylation signatures have emerged as stable and optimal targets for clinical translation. Because DNA methylation alterations (e.g., hypermethylation of specific tumor-suppressor promoters) occur as early, ubiquitous events in metastasis, these epigenetic footprints are currently being transformed into robust, PCR-based biomarker panels for liquid biopsies. In the realm of AI, these genome-wide methylation matrices are no longer analyzed in isolation but are increasingly utilized as high-fidelity, vectorized inputs for multimodal machine learning classifiers, acting as the molecular anchor for predicting occult nodal status.

Transcriptomics, Proteomics, and Metabolomics

For prediction of OCLNM in clinical practice, transcriptomic and proteomic discoveries are translated into spatial pathology and multiplexed clinical assays. Advanced spatial transcriptomics and multiplex immunohistochemistry are applied directly to whole-slide images. This allows for precise in situ quantification of metastasis-associated proteins (e.g., PARVB, VEGF, and the E-cadherin/N-cadherin ratio) within specific tumor microenvironment niches [35]. By digitizing these proteomic and cellular interactions, pathologists can generate “spatial pathomic signatures.” These signatures can be seamlessly integrated with macroscopic imaging data to augment the predictive accuracy of AI-assisted diagnostic pipelines.

Liquid Biopsy and the Microbiome

The most direct clinical application of multi-omics in predicting OCLNM is the development of noninvasive, dynamic monitoring pipelines. Liquid biopsy technologies quantifying circulating tumor DNA, cell-free DNA, and exosomal contents are shifting OCLNM assessment from surgical pathology assessments, which provide a snapshot of a single point in time, to real-time surveillance. Furthermore, the application of machine learning has unlocked the diagnostic value of the intratumoral microbiome. A prime example is the MicroAIbiome framework, an applied machine-learning pipeline that bypasses traditional mechanistic analysis, using the relative abundance of microbes at the genus level (e.g., Fusobacterium) as algorithmic features to classify major malignancies, including HNSCC, with an accuracy of 78.23% [36]. These computational pipelines exemplify the transition from histological approaches to identifying OCLNM to automated, AI-driven clinical approaches.

AI and Machine Learning in OCLNM Assessment

In recent years, the application of AI and machine learning in predicting tumor LNM has advanced at an unprecedented pace. To overcome the inherent limitations of conventional morphological imaging, investigators have advanced AI methodologies across underlying computational models, feature extraction algorithms, and overarching research paradigms. These technological leaps, from basic image classification networks to the decoding of complex spatial heterogeneity and progressing toward cross-modal fusion and survival-driven risk stratification, have reshaped the landscape of precision diagnosis.

Convolutional Neural Networks and Baseline Models

Early AI applications for assessing the risk of LNM predominantly employed classical convolutional neural networks (CNNs), such as ResNet and VGG architectures, for the binary classification of nodal status on the basis of data from CT or MRI [37, 38]. These pioneering end-to-end models bypassed the need for complex hand-crafted features by autonomously extracting hierarchical textures, edge delineations, and morphological patterns from manually cropped regions of interest or image patches. Clinical validations of these baseline models have consistently demonstrated performance comparable to or even exceeding that of mid-level radiologists. For instance, a recent prospective study by Xu et al. utilized a CNN model trained on a massive dataset of contrast-enhanced CT images to diagnose CLNM in oral SCC. The model consistently achieved an area under the receiver operating characteristic curve ranging from 0.85 to 0.90, substantially better than the results reported with human visual assessment [39]. Similar large-scale retrospective evaluations have further corroborated the robust baseline efficacy of CNNs in diagnosing CLNM in head and neck malignancies [40].

However, despite these promising performance metrics, standard CNNs typically processes the entire primary tumor or lymph node as a monolithic, homogeneous region. This whole-region pooling approach inevitably averages out the pixel intensities across the lesion, thereby diluting critical high-risk signals (e.g., microvascular proliferation) with the “noise” of necrotic cores or dense fibrotic stroma. Consequently, standard CNNs have limited capacity to capture highly localized, microscopic spatial cues and intratumoral heterogeneity, which are the fundamental biological prerequisites for identifying early-stage OCLNM.

Evolution of Feature Extraction: Interrogation of Spatial Heterogeneity

The internal architecture of HNSCC is heterogeneous, frequently characterized by central ischemic necrosis, fibrosis, and a proliferative peripheral invasive front with dense microvascular infiltration.

In contrast with traditional CNNs, which treat the tumor as homogeneous, recent research paradigms emphasize refined interrogation of spatial heterogeneity. Peritumoral radiomics represents a major advance in this field. By algorithmically expanding the tumor boundary outward (e.g., by 3 to 5 mm), this approach captures features of the tumor invasive front, early lymphovascular invasion, and desmoplastic responses. Xu et al. [41] demonstrated in hypopharyngeal SCC that combined extraction of gross tumor volume and peritumoral margins on contrast-enhanced CT significantly improved prediction of lymphovascular invasion and metastatic potential compared with extraction of intratumoral features alone.

Habitat radiomics further dissects intratumoral microecology. Using unsupervised clustering algorithms such as K-means, habitat radiomics allows tumors to be automatically partitioned into physiologically distinct subregions (“habitats”), such as low-enhancement ischemic/necrotic zones and high-enhancement hypervascular zones [42]. Targeted extraction of deep learning features from high-risk habitats reduces interference from necrotic tissue and amplifies predictive signals for occult metastasis.

Multi-Regional Spatial Linkage and Cross-Modal Fusion

Regional LNM involves clonal evolution of the primary tumor, basement membrane invasion, lymphatic migration, and regional nodal colonization. Restricting analysis to the primary lesion leads to incomplete predictive information.

Recent computer vision architectures, particularly Vision Transformers, have facilitated clinical implementation of multi-regional spatial linkage. Song et al. [43], in a large real-world cohort of 811 patients with oropharyngeal carcinoma, employed a Swin Transformer architecture to simultaneously extract features from both the primary tumor and cervical lymph nodes. Through global self-attention mechanisms, the model captured intrinsic associations between anatomically distant regions. Notably, even morphologically normal cN0 lymph nodes may exhibit subtle internal texture alterations reflecting biological remodeling driven by the primary tumor.

To overcome the limitations of single-modality data, cross-modal fusion strategies have been widely introduced. Li et al. [44] rigorously evaluated various fusion approaches in a multicenter cohort of tongue SCC. Their findings indicated that late fusion (decision-level fusion), which integrates MRI-based deep learning probability scores, intratumoral heterogeneity radiomic features, and key clinical anchor variables (e.g., depth of invasion, T category) through logistic regression, demonstrated better generalizability and robustness than early feature concatenation did.

Furthermore, Qi et al. [45]. used dual-energy CT-based deep learning models employing channel stacking techniques to input iodine maps, fat maps, and virtual monoenergetic images (70 keV) into a Crossformer Transformer network, providing a functional imaging perspective beyond morphology. The integration of anatomical and perfusion-related information offers improved diagnostic performance for detecting very small occult nodal metastases.

Toward Clinical Trust: Uncertainty Awareness and Survival Risk Reshaping

As AI diagnostic performance approaches technical limits, research emphasis has shifted toward clinical safety and interpretability.

Occult metastases often exhibit subtle and ambiguous imaging characteristics. Conventional deep neural networks tend to be overconfident, assigning definitive predictions even for uncertain lesions, thereby posing potential clinical risks. Uncertainty-aware deep learning has emerged as a solution. De Biase et al. [46] introduced Bayesian mechanisms or Monte Carlo dropout into multicenter segmentation models, enabling quantification of predictive uncertainty. In addition to segmentation outputs, the models generated tumor probability maps, highlighting low-confidence regions and guiding targeted radiologist intervention within a human-in-the-loop framework.

More fundamentally, the ultimate clinical objective of AI in assessing possible OCLNM is shifting from binary diagnosis toward survival risk stratification and restaging. In a study published in Journal of Clinical Oncology, Ye et al. developed an automated deep learning pipeline to quantify total nodal burden and extranodal extension from preoperative imaging in oropharyngeal carcinoma [20]. These AI-derived metrics were incorporated into Cox proportional hazards models to predict overall survival and progression-free survival. The results demonstrated that AI could identify a substantial subset of patients misclassified as “low risk” by the clinical staging system in the eighth edition of the AJCC Cancer Staging Manual who actually exhibited poor outcomes. This AI-driven risk reshaping provides robust evidence to guide future treatment de-escalation or intensified neoadjuvant therapy.

Digital Pathology and Spatial Transcriptomics

Digital pathology (whole-slide imaging) and high-resolution image analysis have promoted the informatized management of large samples. AI improves the detection ability of microscopic signs such as minimal extranodal extension, tumor budding, and metastatic nodules in pathological Sect [47]. Recent studies show that integrating molecular labels with digital pathology images can achieve automatic quantification of immune cell composition in the microenvironment and quantitative correlation of substructures, providing a high-throughput tool for establishing “microscopic pathological scales” and dynamic follow-up [48].

In a study published in Cell Reports Medicine, Oh et al. used spatial analysis techniques and found that the spatial organization of CCR7-positive dendritic cells in niches predicted patient response to pembrolizumab treatment and overall survival better than traditional combined positive score did [49]. This finding highlights the importance of spatial omics in understanding the tumor immune microenvironment and predicting treatment response.

Cross-Scale Multimodal Fusion

In addressing the challenge of precision diagnosis for OCLNM, reliance on the single data modality leaves “information blind spots.” Medical imaging (e.g., contrast-enhanced CT or MRI) provides a global view of macroscopic spatial heterogeneity but lacks cellular-level resolution. Conversely, whole-slide digital pathology images, despite being the microscopic gold standard, are constrained by spatial sampling bias.

To overcome these intrinsic limitations, cross-scale multimodal fusion, integration of imaging, pathology, and epigenetic data, has emerged as the ultimate precision oncology paradigm [50]. Combining macroscopic peritumoral habitat features from medical imaging with microscopic indicators from whole-slide images significantly improves predictive performance in various solid tumors, including HNSCC [51,52,53].

Emerging research is embedding genome-wide DNA methylation profiles into this multidimensional architecture [54]. Local epigenetic reprogramming, such as methylation-driven angiogenesis, inevitably translates into altered tissue density and abnormal imaging textures [55]. By capturing the tumor ecosystem from phenotype to genotype, these high-fidelity multi-omics signatures enable a noninvasive “panoramic virtual biopsy,” providing an integrated anatomical, cellular, and molecular basis for resolving the OCLNM clinical dilemma (Fig. 3).

Fig. 3

Multimodal deep learning architecture for head and neck–specific OCLNM prediction. The imaging branch encodes radiomic features from axial cervical CT/MRI slices encompassing the primary tumor and regional lymphatic basin. The digital pathology branch extracts high-dimensional spatial features from whole-slide images, capturing microinvasion and immune features. The genomic/epigenetic branch integrates vectorized DNA methylation matrices and mutation signatures as stable molecular predictors. Feature embeddings from each modality are harmonized through late-fusion integration to generate probabilistic metastasis predictions. Auxiliary modules incorporate uncertainty quantification and explainable attention mapping to enhance clinical interpretability and safety. This architecture exemplifies the transition from single-modality classification toward biologically informed, uncertainty-aware multimodal risk modeling